Author Interviews, Surgical Research / 03.11.2020

MedicalResearch.com Interview with: Dr. Pravesh S. Gadjradj, MD Department of Neurosurgery, Leiden University Medical Center, University Neurosurgical Center Holland Leiden, Netherlands neurosurgery brain surgery ct scan MedicalResearch.com: What is the background for this study? What are the main findings?  Response: Many healthcare professionals throughout the world face issues surrounding medical malpractice at some point in their careers. Unfortunately, a number of these cases turn into medical malpractice lawsuits. As a specialty that treats acute pathology and refractory pain, neurosurgery is at risk for high liability. By the means of a survey among members of the Congress of Neurological Surgeons (CNS), we aimed to illustrate how malpractice lawsuits affect neurosurgeons professionally, emotionally and financially.   MedicalResearch.com: What are the main findings?  Response: Some 490 members of the CNS shared their experiences with us. Among these members, 81% faced a medical malpractice lawsuit. The main concerns expressed about being sued included losing confidence and practicing defensive medicine, personal assets being at risk, and being named in the National Practitioner Data Bank. Of the respondents, 40% stated they were frequently or always concerned about being sued, and 77 % stated their fear had led to a change in how they practice medicine. For 58 %, this change led to the practice of defensive medicine, while for others it led to more extensive documentation (14%) and/or to referring or dropping complex cases (12%). Given the medical malpractice environment, 59% of respondents considered referring complex patient cases, whereas 37% considered leaving the practice of medicine. (more…)
Author Interviews, Brigham & Women's - Harvard, COVID -19 Coronavirus, Occupational Health / 03.11.2020

MedicalResearch.com Interview with: Fan-Yun Lan, MD, MS PhD candidate in Population Health Sciences | Environmental Health Graduate School of Arts and Sciences & T.H. Chan School of Public Health Harvard University MedicalResearch.com: What is the background for this study? Response: Existing evidence has indicated that essential workers are heavily affected by the COVID-19 pandemic, as they are not able to benefit from mitigation policies. Their occupational exposures increase their own risk to SARS-CoV-2 infection, and increase the risk of secondary transmissions to their colleagues, families and communities. Research, however, has largely focused on healthcare workers with relatively limited literature investigating non-healthcare essential workers. (more…)
Author Interviews, Cancer Research, Journal Clinical Oncology, University of Pittsburgh / 03.11.2020

MedicalResearch.com Interview with: Kristine Gade, MD Hematology/Oncology Fellow UPMC Hillman Cancer Center MedicalResearch.com: What is the background for this study? Would you briefly describe the “surprise question”?  Response:  Via Oncology Pathways, a cancer care platform used by UPMC and other institutions across the country, asks physicians to answer the surprise question – “Would I be surprised if this patient died in the next 12 months?” – whenever a new treatment plan is implemented.   This question has been widely adopted by many oncology and palliative care frameworks and has been shown to be modestly predictive of mortality in multiple studies.  We know that advanced cancer patients have a high utilization of the emergency department, even near end of life.  Our group wanted to see if we could use the results of the surprise question to easily and quickly communicate to emergency department providers the expected prognosis for our advanced cancer patients.  First, we set out to assess the surprise question’s ability to predict survival among our UPMC Hillman Cancer Center patients with select stage IV cancer diagnoses.   (more…)
Asthma, Author Interviews / 03.11.2020

MedicalResearch.com Interview with: https://www.gsk.com/en-gb/home/Beth Hahn, PhD, Director U.S. Value Evidence and Outcomes, GlaxoSmithKline, Research Triangle Park, NC MedicalResearch.com: What is the background for this study? Response: Biologic therapies are increasing as a treatment for patients with severe asthma, with multiple therapies approved by the FDA.  There is also an increasing understanding of the factors influencing preference for and adherence to biologic therapies for patients with severe asthma; however, little is known about why patients discontinue biologic therapy. In patients who have access to biologic treatment, understanding the circumstances and asthma characteristics associated with discontinuation of biologic therapy may allow for the identification of barriers to treatment success . The objective of this study of cross-sectional physician and patient survey data was to assess the patient characteristics and the given reasons for treatment discontinuation in a US patient cohort with severe asthma treated with biologic therapy. A total of 117 physicians and 285 patients completed surveys with 70% of patients continuing biologic therapy (N=200). This study included a number of different FDA approved biologics. From the perspectives of the physicians included in the current study (85 providing a rationale for discontinuation), the majority reported a lack of symptom control, particularly shortness of breath (46%), exacerbations (26%) and other chronic symptoms (29%), as a key reason for discontinuing biologic therapy in severe asthma. Symptom control was also key for patients, with these three symptom categories among their top six reasons for biologic discontinuation. The cost of biologic treatment was also an important factor, cited as the 5th most common reason for discontinuation among physicians and the 3rd among patients. (more…)
Author Interviews, COVID -19 Coronavirus, JAMA / 02.11.2020

MedicalResearch.com Interview with: Darpun D. Sachdev, M.D. Case investigation and Contact tracing Branch Chief SFDPH Covid Command Center San Francisco Department of Public Health MedicalResearch.com: What is the background for this study? What are the main findings? Response: The ultimate goal of contact tracing is to rapidly identify and isolate contacts who are COVID-19 positive before they have time to transmit to others. As mentioned in the published research letter by SFDPH, through JAMA, during early shelter-in-place (from April to June 2020), our contact tracing program successfully reached greater than 80% of cases and contacts within a median timeframe of 6 days from the onset of their case’s symptoms. Approximately 10% of named contacts were newly diagnosed with COVID-19 (compared to 2% positivity during this time period). Household contacts made up approximately 80% of all identified contacts, but 90% of contacts who tested positive lived in the same household as the case. Secondary cases (contacts who were found to be newly diagnosed with COVID-19) were traced and quarantined within 6 days of the case’s symptom onset. With that said, the 6-day time difference between symptom onset and contact notification raises concern regarding the overall effectiveness of tracing in preventing onward transmission by infected contacts. We are working with community-based organizations to scale up access to testing and culturally competent tracing and wraparound services. Currently, we have now decreased the time difference to 5 days. Moreover, given that the majority of contacts resided in the same household, transmission could have occurred presymptomatically such that by the time infected contacts were identified, they might have already transmitted the virus. Hence, why SFDPH, on May 5, 2020, implemented the recommendation of universal testing for COVID-19 contacts, regardless of symptoms. We recommend that testing should be offered to all contacts regardless of symptoms and encourage local health departments to adopt novel ways of increasing testing access for contacts.    (more…)
Author Interviews, COVID -19 Coronavirus, Gastrointestinal Disease / 01.11.2020

MedicalResearch.com Interview with: Darbaz Adna​n, MBChB Lab Research Assistant Department of Internal Medicine - Section of Gastroenterology Rush University Medical Center Chicago, Illinois 60612 MedicalResearch.com: What is the background for this study? Response: - We have conducted a large study of over 1000 patients at a major COVID-19 response center in Chicago at Rush University Medical Center, to assess for the frequency of initial GI symptoms (diarrhea, vomiting, abdominal pain) and evaluate whether these symptoms in adult COVID-19 positive could predict the disease course. Overall, 22.4% of our patients reported at least one GI symptom at the onset of their infection, with nausea/vomiting being the most common complaint. GI symptoms in COVID-19 patients were associated with worse outcomes. (more…)
Author Interviews, Cleveland Clinic, Infections / 31.10.2020

MedicalResearch.com Interview with: MedicalResearch.com Interview with: Curtis J. Donskey, MD Professor of Medicine Case Western Reserve University Staff Physician, Infectious Diseases Section, Louis Stokes Cleveland VA Medical Center MedicalResearch.com: What is the background for this study? Response: The goal of the study was to obtain a better understanding of how healthcare-associated pathogens are transmitted.  Infection control efforts tend to emphasize hand hygiene and cleaning of high-touch surfaces in patient rooms.  However, there is evidence that portable equipment and floors could be underappreciated sources of transmission. We previously found that a nonpathogenic virus inoculated onto floors in patient rooms spread rapidly to the hands of patients and to surfaces in the room and throughout the ward.  This raised concern that pathogens could spread by the same route. (more…)
Author Interviews, Cancer Research, Dermatology, JAMA / 30.10.2020

MedicalResearch.com Interview with: Selin Tokez, PhD Student Department of Dermatology Erasmus MC, Rotterdam MedicalResearch.com: What is the background for this study? Response: Cutaneous squamous cell carcinoma (cSCC) is the second most common skin cancer worldwide with still increasing incidence rates. Given these high incidence rates together with the associated health costs and possibility of fatal progression, it is extremely important to have accurate and complete data on the epidemiology of this disease. Nevertheless, national cancer registries in many countries do not routinely record cSCC cases and therefore currently known numbers are mainly based on incomplete data sources. Additionally, if cSCC cases are registered, this usually only concerns the first cSCC per patient while we know that, contrary to many other malignant neoplasms, patients may develop numerous cSCCs over time. MedicalResearch.com: What are the main findings? Response:  In the present study, we analyzed Dutch nationwide data comprising about 145,000 patients with a first invasive cSCC diagnosis between the years 1989 and 2017. We found that the incidence rates of a first cSCC per patient almost tripled in male patients and increased about fivefold in female patients in this 30-year time period. Also, we had data on all cSCCs per patient for the year 2017 and could therefore compare this with the data on only the first cSCC per patient: incidence rates increased by 58% for men and 35% for women when multiple cSCCs were considered. In absolute numbers, this resulted in an increase of 45% in cSCC diagnoses in 2017. Lastly, we extended our analyses by predicting future cSCC incidence rates up to 2027. Given that no substantially effective measures are undertaken in the near future, current cSCC incidence rates will increase with 23% in males and 29% in females in the next decade. (more…)
AHA Journals, Author Interviews, Heart Disease, Surgical Research / 30.10.2020

MedicalResearch.com Interview with: Stavros G. Drakos, MD, PhD, FACC Professor of Cardiology Univ. of Utah Healthcare & Medical School and the Salt Lake VA Medical Center. Dr. Drakos is Medical Director of the University's Cardiac Mechanical Support/Artificial Heart Program Co-Director Heart Failure & Transplant and Director of Research for the Division of Cardiology MedicalResearch.com: What is the background for this study? Response: Heart transplantation and LVADs are first line therapies for advanced chronic heart failure. There were some earlier anecdotal observations and single center small studies from several programs in the US and overseas that left ventricular assist devices (LVADs) significantly reduce the strain on failing hearts and in some cases, using LVADs for limited periods of time has allowed hearts to “rest” and remodel their damaged structures. As a result of these repairs, described as “reverse remodeling,” heart function can improve to the point that the LVAD can be removed. The new study sought to broaden the reach of the research with a multicenter trial involving physicians and scientists at the University of Utah Health, the University of Louisville, University of Pennsylvania, the Albert Einstein College of Medicine/Montefiore Medical Center, the Cleveland Clinic, and the University of Nebraska Medical Center.  (more…)
Author Interviews, Exercise - Fitness, OBGYNE, Weight Research / 30.10.2020

MedicalResearch.com Interview with: Suvi Ravi Faculty of Sport and Health Sciences University of Jyväskylä Jyväskylä, Finland MedicalResearch.com: What is the background for this study? Response: The results of studies comparing the prevalence of menstrual dysfunction in athletes and non-athletes have been inconsistent. Menstrual dysfunction can have many different causes but one of the most common in athletes is low energy availability (i.e., inadequate energy intake relative to energy expenditure). Disordered eating/eating disorder as a result of e.g. body weight dissatisfaction, which is the discrepancy between actual and desired weight, can be a risk factor for inadequate energy intake and thus could play a role in menstrual dysfunction. We studied a cohort of athletes and non-athletes, in adolescence (14-16 years) and subsequently in young adulthood (18-20 years) to determine the prevalence of menstrual dysfunction and body weight dissatisfaction. Menstrual dysfunction in our study was defined as primary amenorrhea, which is the absence of menses by the age of 15, prolonged menstrual cycle (>35 days), or secondary amenorrhea i.e., absence of menses for at least three consecutive months.  (more…)
Author Interviews, Dermatology, Inflammation / 30.10.2020

MedicalResearch.com Interview with: Dr. Douglas Maslin, MPhil, MB BCHir Dermatologist and Pharmacologist Addenbrooke's Hospital Cambridge, UK   MedicalResearch.com: What is the background for this study? Response: I’d like to answer this question in three parts: EVELO BIOSCIENCESFirstly, the background to Evelo and the therapeutic EDP1815: Evelo is developing orally administered biologic medicines based on a new understanding of how systemic inflammation is controlled. Evelo’s medicines are selected for their ability to modulate the small intestinal axis, or SINTAX, a network of anatomical and functional connections that has evolved to connect the small intestine with the rest of the body. SINTAX links small intestinal mucosal immunology with systemic inflammation and is now accessible with oral medicines. This inflammatory control pathway may enable a new class of products which are effective, safe, and can be manufactured affordably at large scale. EDP1815 is a non-live pharmaceutical preparation of a strain of the bacterium Prevotella histicola isolated from the duodenum of a human donor. Its pharmacodynamic effect is through interactions with the immune cells within the small intestine and it has no systemic absorption. These local interactions in the small intestine then downregulate systemic inflammation. In fact, the inflammatory control afforded by targeting the small intestinal axis appears to result in the coordinated downregulation of multiple inflammatory pathways without immunosuppression, mimicking the body’s normal physiological processes of inflammation resolution. Secondly, there is the key and exciting background pre-clinical data on EDP1815 – the details of which have been published today at the EADV conference. For example, oral administration of EDP1815 to mice has been shown to lead to striking therapeutic effects in in vivo models of delayed-type hypersensitivity, imiquimod-induced skin inflammation, fluorescein isothiocyanate cutaneous hypersensitivity, collagen-induced arthritis, and experimental acute encephalomyelitis (EAE). The consistency of effect and dose shows that EDP1815 can coordinately resolve systemic inflammation across TH1, TH2 and TH17 pathways. This suggests the potential for clinical benefit across multiple diseases. And, thirdly, there is the clinical unmet need for an oral, safe, effective treatment specifically for mild and moderate psoriasis patients, who have very limited treatment options outside of the poorly tolerated topical therapies, and these patients are reported to be dissatisfied with treatment options and therefore are often under-treated. These three points explain the background to EDP1815 and the reason for progressing forward into the phase 1b in psoriasis. (more…)
Author Interviews, Brigham & Women's - Harvard, COVID -19 Coronavirus, Insomnia, Obstructive Sleep Apnea, Sleep Disorders / 29.10.2020

MedicalResearch.com Interview with: Salma Batool-Anwar, MBBS, MPH Instructor, Harvard Medical School Pulmonary and Critical Care, Sleep Medicine Brigham and Women's Faulkner Hospital MedicalResearch.com: What is the background for this study? Response: A well functioning sleep-wake cycle is vital to our health and prevention of chronic diseases. During previous disaters sleep disturbances have been reported. When Massachusetts governor declared a state of emergency in March’20, we hypothesized that sleep duration would be adversely affected by covid-19 related lockdown and stress. The study was approved by the institutional review board and information was collected retrospectively using the electronic medical records.  (more…)
Author Interviews, Fertility, Genetic Research, OBGYNE, Technology / 29.10.2020

MedicalResearch.com Interview with: PGT-A & ARTIFICIAL INTELLIGENCE IMPROVES PREGNANCY OUTCOMES FOR PATIENTS UNDERGOING IVF MedicalResearch.com Interview with: Michael Large, PhD Senior Director, Research at CooperGenomics CooperSurgical MedicalResearch.com: What is the background for this study? What are the main findings? Dr. Large: Independent study results, presented at the recent the American Society of Reproductive Medicine (ASRM) Virtual Scientific Congress, demonstrated a 13 percent relative increase in ongoing pregnancy and live birth rates associated with the use of CooperSurgical’s PGTaiSM 2.0 technology to screen embryos for in vitro fertilization (IVF). The single-center study was conducted by NYU Langone Fertility Center (NYULFC), part of The Prelude Network. Preimplantation Genetic Testing for aneuploidy (PGT-A) is performed on embryos produced through IVF; it provides genetic information to help identify embryos that are more likely to result in a successful pregnancy. PGTai 2.0 technology is an advancement in PGT-A testing platform that utilizes artificial intelligence to increase objectivity of this screening process. The study compared results from three next generation sequencing (NGS) genetic tests: Standard NGS, NGS with first generation artificial intelligence (PGTai 1.0 Technology Platform) and NGS with second generation artificial intelligence (PGTai 2.0 Technology Platform). The ongoing pregnancy and live birth rates significantly increased by a relative 13 percent in the PGTai 2.0 group as compared to subjective and prior methodologies. Study results also suggest that the increase in ongoing pregnancy and live births may be linked to improvements in several preceding IVF outcomes (implantation rates, clinical pregnancy rates and pregnancy loss.) MedicalResearch.com: What should readers take away from your report? Dr. Large: This research moves us an important step closer to our goal of increased live births, improved pregnancy outcomes and further reduction of multiples in pregnancy through greater confidence in single embryo transfer. An estimated 48.5 million couples – approximately 15% of couples -- are affected by infertility worldwide. 80,000 babies were born with IVF in 2017 in the United States and more than one million babies were born in the period 1987 to 2015 in the United States as a result of IVF. MedicalResearch.com: What recommendations do you have for future research this study? Dr. Large: The goal of PGT-A is to decrease risk and maximize the chances of IFV success by screening for embryos with the highest potential. This was precisely what NYULFC have observed so far with PGTai 2.0 compared to older technologies. To fully appreciate the impact that these improvements are having for patients, we’re excited to hear from additional IVF centers across the world as they utilize this technology. MedicalResearch.com: Is there anything else you would like to add? Any disclosures? Dr. Large: The study demonstrates CooperSurgical’s commitment to developing the most advanced technology in the field of genetic testing to advance reproductive medicine and help families. By applying artificial intelligence in the PGTaism2.0 technology, we leverage mathematical algorithms derived from real-world data to achieve objective embryo assessment. I am the Senior Director of Genomics Research and Development at CooperSurgical. Michael Large, PhD, is the Senior Director, Genomics Research and Development at CooperSurgical. His team recently led and continues to develop state-of-the-art analytical methods for interrogating Reproductive Genetics. Dr. Large earned his PhD in Cell and Molecular Biology from the Baylor College of Medicine and his Bachelor of Science in Cell and Molecular Biology from the University of Wisconsin – La Crosse. Michael Large, PhD Senior Director, Research at CooperGenomics CooperSurgical   MedicalResearch.com: What is the background for this study? What are the main findings? Dr. Large: Independent study results, presented at the recent the American Society of Reproductive Medicine (ASRM) Virtual Scientific Congress, demonstrated a 13 percent relative increase in ongoing pregnancy and live birth rates associated with the use of CooperSurgical’s PGTaiSM 2.0 technology to screen embryos for in vitro fertilization (IVF).[1] The single-center study was conducted by NYU Langone Fertility Center (NYULFC), part of The Prelude Network. Preimplantation Genetic Testing for aneuploidy (PGT-A) is performed on embryos produced through IVF; it provides genetic information to help identify embryos that are more likely to result in a successful pregnancy. PGTai 2.0 technology is an advancement in PGT-A testing platform that utilizes artificial intelligence to increase objectivity of this screening process. The study compared results from three next generation sequencing (NGS) genetic tests: Standard NGS, NGS with first generation artificial intelligence (PGTai 1.0 Technology Platform) and NGS with second generation artificial intelligence (PGTai 2.0 Technology Platform). The ongoing pregnancy and live birth rates significantly increased by a relative 13 percent in the PGTai 2.0 group as compared to subjective and prior methodologies. Study results also suggest that the increase in ongoing pregnancy and live births may be linked to improvements in several preceding IVF outcomes (implantation rates, clinical pregnancy rates and pregnancy loss.) (more…)
Author Interviews, Dermatology / 28.10.2020

MedicalResearch.com Interview with: Dr. Linda Stein Gold MD Director of Dermatology Clinical Research at Henry Ford Health System Detroit, Michigan Division Head of Dermatology Henry Ford Health System in West Bloomfield, Michigan MedicalResearch.com: What is the background for this study? Response: Halobetasol and Tazarotene work by complimentary mechanisms of action in treating psoriasis and also have been shown to counteract the side effects associated with the other medications. In prior studies using tazarotene as monotherapy, there was a maintenance of effect even after the drug was discontinued. We investigated to see if there was a maintenance of treatment effect in patients who achieved clear skin after using the fixed combination of halobetasol propionate 0.01%/tazarotene 0.045% lotion for 8 weeks of daily treatment. 

I served as lead author on the study, which was presented Fall Clinical Dermatology Conference this weekend in a poster titled, “Long-term management of moderate-to-severe plaque psoriasis: maintenance of treatment success following cessation of halobetasol propionate 0.01%/tazarotene 0.045% lotion.”

(more…)
Author Interviews, COVID -19 Coronavirus, Health Care Systems, JAMA, Technology / 27.10.2020

MedicalResearch.com Interview with: Shira H. Fischer, MD, PhD RAND Corporation Boston, Massachusetts MedicalResearch.com: What is the background for this study? What are the main findings? Response: Before the COVID-19 outbreak, telehealth was talked about a lot, but it wasn’t widely available and wasn’t used that often. We wanted to know who was using telehealth, what the barriers to use were, and whether people would be willing to do so if it were available to them. We conducted a survey of over 2,500 Americans across the country and asked them about these topics.  (more…)
Author Interviews, COVID -19 Coronavirus, Health Care Systems / 27.10.2020

MedicalResearch.com Interview with: Steve Olin Chief Product Officer Rally Health, Inc., part of the Optum business of UnitedHealth Grou MedicalResearch.com: Can you please elaborate on Rally Health’s mission? Mr. Olin: Our founding mission 10 years ago and still to this day is to put health in the hands of the individual. As a digital health company, we live this mission through our focus in three key areas: 1) Providing digital-first access to care by giving individuals easy-to-use digital tools and support to navigate their health care and take full advantage of their health benefits; 2) Engaging people in their daily health by creating experiences that people enjoy and that inspire them to perform healthy actions, and by giving them access to resources that help them achieve their health goals; 3) Saving people time and money by providing digital tools that help them understand health care costs and guide them to lower-cost, high-quality care options. (more…)
Author Interviews, Heart Disease, JACC, Omega-3 Fatty Acids / 27.10.2020

MedicalResearch.com Interview with: Antoni Bayes-Genis, MD, PhD, FESC, FHFA Head, Heart Institute. Hospital Universitari Germans Trias i Pujol Full Professor, Autonomous University Barcelona MedicalResearch.com: What is the background for this study? What are the main findings? Response: Omega-3 fatty acids are incorporated into the phospholipids of cellular membranes, including cardiac contractile cells, and have a wide range of demonstrated physiological effects. Several potential mechanisms have been investigated, including antiarrhythmic, anti-inflammatory, and endothelial. Omega-3 fatty acids lower heart rate and improve heart rate variability, both associated with lower sudden cardiac death risk, one of the complications that may occur after a myocardial infarction. Increased omega-3 fatty acids also enhance arterial elasticity by increasing endothelium-derived vasodilators, which is associated with blood pressure–lowering effects. They also have a cardioprotective effect on platelet-monocyte aggregation, and lower triglyceride levels. (more…)
Author Interviews, Cognitive Issues, Emory, Exercise - Fitness, Heart Disease / 27.10.2020

MedicalResearch.com Interview with: Henry Mahncke, PhD Chief Executive Officer Posit Science https://www.brainhq.com/?v4=true&fr=yDr. Mahncke earned his PhD at UCSF in the lab where lifelong brain plasticity was discovered. At the request of his academic mentor, he currently leads a global team of more than 400 brain scientists engaged in designing, testing, refining, and validating the computerized brain exercises found in the BrainHQ app from Posit Science, where he serves as CEO. MedicalResearch.com Tell us what’s important about this new study in people with heart failure? Response: Heart failure is a common condition that even when properly treated can have adverse long-term health outcomes and high medical costs. Heart failure commonly causes cognitive impairment, which can have devastating effect on patient abilities to engage in self-care, and which contributes to poor clinical outcomes, increased rehospitalizations, and higher mortality rates. What makes these results exciting is that the Emory University researchers discovered that a simple intervention – a fairly modest amount of walking and brain exercise – not only significantly improved a standard measure of cognition, but also significantly improved multiple measures that drive better health outcomes and lower costs. MedicalResearch.com: What is heart failure? Response: Heart failure – sometimes called congestive heart failure or congestive cardiac failure – is when the heart cannot pump sufficient blood flow to maintain the body’s needs. Common symptoms include excessive tiredness, shortness of breath and swelling particularly in legs. It’s treated with a combination of lifestyle changes, drugs, and devices. An estimated 6.5 million Americans are diagnosed with heart failure, with 960,000 new cases each year, leading some to describe it as reaching epidemic proportions. In older adults, it’s the most common cause of hospital readmissions within 30 days of discharge and among the most costly areas of Medicare expenditures. (more…)
Author Interviews, Nutrition, NYU, Pediatrics, Pediatrics, Technology / 26.10.2020

MedicalResearch.com Interview with: Marie Bragg, PhD Assistant Professor, Department of Population Health on Health Choice NYU College of Global Public Health MedicalResearch.com: What is the background for this study? Response: We know from previous research that children who see food advertisements eat significantly more calories than children who see non-food advertisements. Those studies led the World Health Organization and National Academy of Medicine to issue reports declaring that exposure to food advertising is a major driver of childhood obesity. What we don’t know is how frequently unhealthy food and beverage brands are appearing in YouTube videos posted by Kid Influencers. Kid influences are children whose parents film videos of the child playing with toys, unwrapping presents, eating food, or engaging in other family-friendly activities. The parents then post the videos to YouTube for other children and parents to view for entertainment.  (more…)
Author Interviews, Brigham & Women's - Harvard, Heart Disease, JAMA, Lifestyle & Health, Nutrition / 26.10.2020

MedicalResearch.com Interview with: Samia Mora, MD MHS Associate Professor, Harvard Medical School Director, Center for Lipid Metabolomics Brigham and Women’s Hospital Boston, MA 02215 @SamiaMoraMD MedicalResearch.com: What is the background for this study? Response: Couples, both married couples and domestic partners, are likely to share similar environmental exposures, adopt similar behavior patterns, and have similar characteristics. However, the degree to which couples share similar levels of cardiovascular (CV) risk factors and behaviors is uncertain. If high levels of poor CV risk factor measures and behaviors are common in both members of a couple, programs that target improvement of these risk factors and behaviors may simultaneously benefit CV health in both members of the couple. (more…)
Author Interviews, Coffee, Diabetes / 26.10.2020

MedicalResearch.com Interview with: Yuji Komorita, MD, PhD Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University Maidashi 3-1-1, Higashi-ku, Fukuoka MedicalResearch.com: What is the background for this study?   Response: Both green tea and coffee have been reported to confer health benefits, and reduce all-cause mortality in general population, respectively. However, no study has investigated the combined impact of them on health or mortality. We followed 4,923 Japanese patients with type 2 diabetes registered at the Fukuoka Diabetes Registry (median, 5.3 years; follow-up rate, 99.5%).  MedicalResearch.com: What are the main findings?  Response: Drinking 4 or more daily cups of green tea was associated with 40% lower risk of death, and 2 or more cups of coffee was associated with 41% lower risk. Furthermore, the combination of 4 or more cups of green tea and 2 or more cups of coffee every day was associated with 63% lower risk of death. We have shown that higher consumption of green tea and coffee was associated with reduced all-cause mortality, and their combined effect appeared to be additive in people with type 2 diabetes. (more…)
Author Interviews, COVID -19 Coronavirus, Critical Care - Intensive Care - ICUs / 24.10.2020

MedicalResearch.com Interview with: Michael Mazzeffi MD MPH MSc Associate Professor of Anesthesiology Division Chief Anesthesiology Critical Care Medicine Medical Director Rapid Response Team MedicalResearch.com: What is the background for this study? Response: We have known for some time that COVID19 is characterized by hypercoagulability or excess blood clotting.  In fact, the incidence of blood clots in the lungs (pulmonary emboli) is as high 20% and is two to three times more common in COVID19 than in severe influenza.  Further, autopsies of patients who died from COVID19 have shown that endothelial cells (cells that line the blood vessels) are damaged and that "micro clots" form in multiple organs.  Together, these findings strongly suggest that excess blood clotting and endothelial cell dysfunction are defining features of severe COVID19. For several months, my colleagues and I have been interested in whether aspirin might improve outcomes in patients with severe COVID19.  In prior observational research studies, aspirin was found to be protective in patients with severe lung injury.  The general idea is that aspirin reduces platelet aggregates in the lung and this improves outcome.  Unfortunately, in a prior randomized controlled study (LIPS-A) aspirin was not shown to reduce the incidence of acute respiratory distress syndrome.  Nevertheless, COVID19 has unique features that make aspirin more likely to be effective.  Mainly COVID19 is associated with hypercoagulability to a greater degree than in other viral illnesses.  (more…)
Author Interviews, Ophthalmology / 23.10.2020

MedicalResearch.com Interview with: Steven Grieco, PhD Postdoctoral Scholar Xu Lab, UCI MedicalResearch.com: What is the background for this study? Response: In recent years the drug ketamine, which has been used safely as a dissociative anaesthetic for decades, has gained widespread interest in the field of psychiatry for its use as an antidepressant at low doses. In 2019 the FDA finally approved a nasal spray that delivers ketamine to patients with untreatable clinical depression.  Now, such patients go to the appropriate clinical setting and receive ketamine treatments, though this is not required daily for an effective outcome. In fact, studies have found that a single low dose ketamine treatment can result in beneficial improvements in mood that last for several days or even weeks. This suggests that ketamine treatment induces significant neural plasticity in the brain. Since the mechanisms governing this ketamine-mediated neural plasticity were not known, our group studied this using the visual cortex as a model tissue. The visual cortex has perhaps the most well-characterized patterns of neural plasticity in the brain to date, and is an excellent arena in which to test hypotheses about the mechanisms of neural plasticity. In fact, the classical antidepressant fluoxetine (Prozac), which induces neural plasticity only after long-term chronic treatment, has been studied extensivley in the visual cortex as well. (more…)
Author Interviews, Emergency Care, Social Issues, Technology / 23.10.2020

MedicalResearch.com Interview with: Susan Lu PhD Gerald Lyles Rising Star Associate Professor of Management Krannert School of Management Purdue University  MedicalResearch.com: What is the background for this study? Response: We started this project in 2016. Overcrowding in emergency rooms (ERs) is a common yet nagging problem. It not only is costly for hospitals but also compromises care quality and patient experience. Hence, finding effective ways to improve ER care delivery is of great importance. Meanwhile, the advancement of healthcare technologies including electronic medical records, online doctor ratings and 4G mobile network motivates us to think about the impact of telemedicine on ER operations in the near future.  (more…)
Author Interviews, Environmental Risks, Nature, Pediatrics / 23.10.2020

MedicalResearch.com Interview with: Prof. John Boland AMBER The SFI Research Centre for Advanced Materials and BioEngineering Research, CRANN, and Trinity’s School of Chemistry Prof. Liwen Xiao at TrinityHaus and Trinity’s School of Engineering Trinity College Dublin baby-bottle-infant-plasticsMedicalResearch.com: What is the background for this study? Response: There is growing evidence to suggest that micro and nano plastics are released into our food and water sources through the chemical and physical degradation of larger plastic items. Some studies have demonstrated the potential transfer of micro and nano plastics from oceans to humans via the food chain but little is known about the direct release of microplastics (MPs) from plastic products through everyday use – and this is what we wanted to investigate.  Polypropylene (PP) is one of the most commonly produced plastics in the world for food preparation and storage. It is used to make everyday items such as lunch boxes, kettles and infant-feeding bottles (IFBs). Despite its widespread use the capacity of PP to release microplastics was not appreciated until now. We analysed the potential for release of MPs from polypropylene infant-feeding bottles (PP-IFBs) during formula preparation by following international guidelines. We also estimated the exposure of 12-month-old infants to MPs in 48 countries and regions.  (more…)
Author Interviews, Dental Research, Inflammation / 22.10.2020

MedicalResearch.com Interview with: Prof. Michael Glogauer, D.D.S., Ph.D Faculty of Dentistry, University of Toronto Toronto, ON Canada MedicalResearch.com: What is the background for this study? Response: Periodontal disease (PD) affects between 20% and 50% of the global population, with growing evidence supporting its association with other inflammatory diseases, including heart disease, arthritis, and diabetes. Several studies have shown how untreated periodontal disease leads to increased medical care costs for nonoral conditions, including patient hospitalization rates. The interaction of inflammatory diseases with PD suggests a shared, underlying pathology that may be exploited to better manage patients and reduce the economic burden. However, the mechanisms through which these diseases interact are unclear. In periodontal disease, tissue and bone destruction in the mouth is driven by elevated recruitment of white blood cells called polymorphonuclear neutrophils (PMNs), which are activated by the oral disease and recruited from the circulation to sites of inflammation.  (more…)
Asthma, Author Interviews, BMJ, Osteoporosis / 21.10.2020

MedicalResearch.com Interview with: Christos Chalitsios B.Sc, M.Sc PhD student Funded by British Medical Association (BMA) School of Medicine Division of Respiratory Medicine University of Nottingham City Hospital,Nottingham MedicalResearch.com: What is the background for this study? Response: Inhaled (ICS) and oral (OCS) corticosteroids play a crucial role in the control of airway inflammation in asthma. Given that the use of ICS in asthma is likely to increase with the recent change in GINA guidance recommending combined long-acting-β2-agonists with ICS at step 1 and the upward trend in prescribing of OCS, we sought to clarify the link between steroids, osteoporosis and FF in patients with asthma, stratifying the risk by dose, number of courses and type of steroids. The prevalence of patients receiving at least one bisphosphonate was also calculated. (more…)
Author Interviews, Depression, Mental Health Research, Nature, PTSD / 21.10.2020

MedicalResearch.com Interview with: Amit Etkin, MD, PhD Department of Psychiatry and Behavioral Sciences Wu Tsai Neurosciences Institute, Stanford Universitu Stanford, CA    MedicalResearch.com: What is the mission of Cohen Veterans Bioscience - CVB?  Cohen Veterans Bioscience Response: Cohen Veterans Bioscience (CVB) is a non-profit 501(c)(3) research biotech dedicated to fast-tracking the development of diagnostic tests and personalized therapeutics for the millions of Veterans and civilians who suffer the devastating effects of trauma-related and other brain disorders. To learn about CVB’s research efforts visit www.cohenveteransbioscience.org.   MedicalResearch.com: How can patients with PTSD or MDD benefit from this information? Response: With the discovery of this new brain imaging biomarker, patients who suffer from PTSD or MDD may be guided towards the most effective treatment without waiting months and months to find a treatment that may work for them.   MedicalResearch.com: What is the background for this study? Response: This study, which was supported with a grant from Cohen Veterans Bioscience, grants from the National Institute of Mental Health (NIMH and other supporters, derives from our work over the past few years which has pointed to the critical importance of understanding how patients with a variety of psychiatric disorders differ biologically. The shortcomings of our current diagnostic system have become very clear over the past 1-2 decades, but the availability of tools for transcending these limitations on the back of objective biological tests has not kept pace with the need for those tools. In prior work, we have used a variety of methods, including different types of brain imaging, to identify brain signals that underpin key biological differences within and across traditional psychiatric diagnoses. We have also developed specialized AI tools for decoding complex patterns of brain activity in order to understand and quantify biological heterogeneity in individual patients. These developments have then, in turn, converged with the completion of a number of large brain imaging-coupled clinical trials, which have provided a scale of these types of data not previously available in the field. (more…)
Author Interviews, Brigham & Women's - Harvard, COVID -19 Coronavirus, Inflammation, JAMA / 21.10.2020

MedicalResearch.com Interview with: David E. Leaf, MD, MMSc, FASN Assistant Professor of Medicine, Harvard Medical School Director of Clinical and Translational Research in Acute Kidney Injury Division of Renal Medicine, Brigham and Women's Hospital MedicalResearch.com: What is the background for this study? Response: The data for this study were derived from a multicenter cohort study of over 4,000 critically ill patients with COVID-19 admitted to ICUs at 68 sites across the US, as part of the Study of the Treatment and Outcomes in Critically Ill Patients with COVID-19 (STOP-COVID). STOP-COVID was initiated by David E. Leaf, MD, MMSc and Shruti Gupta, MD, MPH, from the Division of Renal Medicine at Brigham and Women’s Hospital and Harvard Medical School. It was initiated in March, 2020 as an unfunded, grassroots network, and now includes over 400 collaborators from 68 sites across the US. Using this data, we used a ‘target trial emulation’ approach to examine whether early administration of the monoclonal antibody, tocilizumab, reduces mortality in critically ill patients with COVID-19. Target trial emulation, a novel method of analyzing observational data, is the idea of simulating a randomized control trial to reduce bias.  (more…)
Author Interviews, Cannabis / 21.10.2020

MedicalResearch.com Interview with: Carrie Cuttler, Ph.D. Assistant Professor Washington State University Department of Psychology Pullman, WA, 99164-4820  MedicalResearch.com: What is the background for this study? Response: While many studies have examined the acute effects of cannabis on other mental health symptoms such as anxiety, depression, post-traumatic stress disorder (PTSD), and psychosis there is almost no research on acute effects of cannabis on symptoms of obsessive-compulsive disorder (OCD) in humans.  Nevertheless, we have previously found that acute cannabis intoxication is associated with reductions in anxiety as well as with reductions in the intrusive thoughts characteristic of PTSD. Further previous research using a rodent model of compulsive behavior has provided pre-clinical evidence that cannabidiol (CBD) - which is the second most common constituent in the cannabis plant - reduces compulsive behavior. (more…)